ALK and non-small cell lung carcinoma: Immune checkpoint inhibitors targeting the PD-1/PD-L1 and CTLA-4 axes are now routinely used alone or in combination with chemotherapy as first-line treatment of metastatic NSCLC that does not harbor an EGFR mutation or ALK/ROS1 rearrangements.